Compare Credo Technology Group Holding Ltd (CRDO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Johnson & Johnson — how do they compare? Credo Technology Group Holding Ltd trades at $215.21 (market cap $39.82B), while Johnson & Johnson trades at $261.04 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 15.5× Credo Technology Group Holding Ltd's market cap, and Johnson & Johnson pays a 2.09% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Johnson & Johnson for 129 Days on average.
| CRDO | JNJ | |
|---|---|---|
Market Cap | $39.82B | $618.09B |
Volume | 9,451,558 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $302.52 | $278.43 |
52-Week Low | $87.81 | $186.00 |
Typical Hold Time | 22 Days | 129 Days |
Enterprise Value | $39.08B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $212.42, down 3.45% today but maintains strong technical support near $204 with bullish moving averages. The company demonstrates exceptional fundamentals with 114.7% YoY revenue growth (Seeking Alpha, 2026-09-25) and 33.83% net margins, though valuation remains elevated at P/E of 74.6. Recent earnings beats and AI infrastructure demand drive positive sentiment.
Outlook remains positive given triple-digit revenue growth and $267.33 analyst price target (87.5% buy ratings), but premium valuation and customer concentration pose risks. The stock offers exposure to AI connectivity chip demand with potential for 26% upside to consensus target, though execution risks require monitoring.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
